Accurately predicting performance of drugs in humans lowers risk and cost of drug development, enabling drug developers to cure more diseases and treat more patients. Such predictive power is provided by Draper’s Human Organ Systems (HOS) technology—precise, high-throughput, scalable and flexible.
A microenvironment that can sustain human tissue organ models for several weeks of automated testing, Draper’s HOS platforms can array 96 independent single organ models in a high-throughput package (PREDICT96), link multiple organ models together (BIOMIMETICS), or culture patient-derived tissue samples (EVIDENT). Use HOS to evaluate drug toxicity, measure efficacy in a disease state such as NASH (non-alcoholic steatohepatitis) and test immune-oncology therapies such as checkpoint inhibitors and combination therapies.
Test varied dosages of drugs simultaneously thanks to the integrated microfluidic pumps in Draper’s HOS that control flow precisely. Collect in vitro data in real time with built-in electrical sensors. Faster testing and clearer indicators from HOS can streamline a drug’s path to success.
Know efficacy and safety better and earlier—before animal tests or clinical trials. Not only more physiologically representative of humans than animal models and faster at less cost, Draper’s HOS can serve a wide array of patient populations.
Harnessing Human Tissue Models for Drug Development
Research shows how organs-on-a-chip can test 96 tissue models at once.
How “Tumor on a Chip” Can Transform Drug Development
Novel device gives cancer researchers and testing labs a tumor environment that has been shown to reduce testing from weeks to days.
Draper Demonstrates Miniature Organ Models Can Play Key Role in COVID-19 Drug Development
New article in bioRxiv points to potential use of organ-on-a-chip in drug discovery for COVID-19 and seasonal flu
Access Our Capabilities
We push boundaries and deliver the capabilities you need.